comparemela.com

Latest Breaking News On - Carol ocallaghan - Page 1 : comparemela.com

Home shows: Where practicality meets style and personality

Legal Aid Service of Broward County Names Brent Thompson as Executive Director and Promotes Debra Koprowski and Carol A O Callaghan to Deputy Executive Directors

Researchers uncover potentially promising therapeutic combination for renal cell carcinoma

 E-Mail Boston, Mass. Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide. Currently, the 5-year survival rate for patients with metastatic RCC is only about 12 percent. Current treatments include inhibitors of the VEGF and PD-1 pathways. However, resistance to therapy occurs in most patients and new combination treatments are still needed to enhance the efficacy of these current approaches. Now, investigators have demonstrated that ACE2 expression is a good prognostic factor in RCC, that loss of ACE2 mediates resistance to classical treatments, and that in preclinical models, treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival. The team, led by Beth Israel Deaconess Medical Center s (BIDMC) Rupal Bhatt, MD, PhD, and University College Cork, Ireland s Thomas Walther, PhD, published

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.